Senores Pharmaceuticals Intrinsic Value
Senores Pharmaceuticals (SENORES) median intrinsic value is ₹491.93 from 8 valuation models (range ₹406–₹700), vs current price ₹1381.90 — -64.4% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse Senores Pharmaceuticals shareholding analysis to track promoter, FII and institutional holdings.
SENORES Valuation Methods Summary — DCF, Graham Number & P/E
Senores Pharmaceuticals intrinsic value across 8 models vs current price ₹1381.90 — upside/downside and value range per method. Read SENORES dividend track record for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹700.48 | ₹560.38 - ₹840.58 | -49.3% | EPS: ₹31.84, Sector P/E: 22x |
| Book Value Method | asset | ₹406.09 | ₹365.48 - ₹446.70 | -70.6% | Book Value/Share: ₹203.04, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹414.57 | ₹373.11 - ₹456.03 | -70.0% | Revenue/Share: ₹167.83, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹565.22 | ₹508.70 - ₹621.74 | -59.1% | EBITDA: ₹260.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹414.57 | ₹373.11 - ₹456.03 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹491.93 | ₹442.74 - ₹541.12 | -64.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹690.95 | ₹621.86 - ₹760.05 | -50.0% | ROE: 15.8%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹414.57 | ₹373.11 - ₹456.03 | -70.0% | EPS: ₹31.84, BVPS: ₹203.04 |
SENORES Intrinsic Value vs Market Price — All Valuation Models
Senores Pharmaceuticals fair value range ₹406–₹700 vs current market price ₹1381.90 across 8 valuation models. For current market price and key ratios, visit SENORES share price.
SENORES Intrinsic Value Analysis — Undervalued or Overvalued?
Senores Pharmaceuticals median intrinsic value ₹491.93, current price ₹1381.90 — Trading Above Calculated Value by 64.4%, margin of safety -100.0%.
What is the intrinsic value of SENORES?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Senores Pharmaceuticals (SENORES) is ₹491.93 (median value). With the current market price of ₹1381.90, this represents a -64.4% variance from our estimated fair value.
The valuation range spans from ₹406.09 to ₹700.48, indicating ₹406.09 - ₹700.48.
Is SENORES undervalued or overvalued?
Based on our multi-method analysis, Senores Pharmaceuticals (SENORES) appears to be trading above calculated value by approximately 64.4%.
SENORES Financial Health — Key Ratios vs Industry Benchmarks
Senores Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.78 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 15.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.48x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
SENORES Cash Flow Quality — Operating & Free Cash Flow
Senores Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-46 Cr | ₹-261 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-26 Cr | ₹-53 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-1 Cr | ₹-25 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-10 Cr | ₹-22 Cr | Negative Cash Flow | 3/10 |